Back to Search Start Over

Safety for Patients With Celiac Disease of Baked Goods Made of Wheat Flour Hydrolyzed During Food Processing

Authors :
Carlo Giuseppe Rizzello
Salvatore Auricchio
Luigi Greco
Francesca Landolfo
Raffaella Di Mase
Renata Auricchio
Angela Cassone
Francesco Paparo
Martina D'Aniello
Maria De Angelis
L. Timpone
Gaetano Terrone
Maria Maglio
Marco Gobbetti
Riccardo Troncone
Raffaella Di Cagno
Greco, Luigi
Gobbetti, Marco
Auricchio, Renata
Di Mase, Raffaella
Landolfo, Francesca
Paparo, Francesco
Di Cagno, Raffaella
De Angelis, Maria
Rizzello, Carlo Giuseppe
Cassone, Angela
Terrone, Gaetano
Timpone, Laura
D'Aniello, Martina
Maglio, Maria
Troncone, Riccardo
Auricchio, Salvatore
Publication Year :
2011

Abstract

Background & Aims: Celiac disease (CD) is characterized by an inflammatory response to wheat gluten, rye, and barley proteins. Fermentation of wheat flour with sourdough lactobacilli and fungal proteases decreases the concentration of gluten. We evaluated the safety of daily administration of baked goods made from this hydrolyzed form of wheat flour to patients with CD. Methods: Patients were randomly assigned to consumption of 200 g per day of natural flour baked goods (NFBG) (80,127 ppm gluten; n = 6), extensively hydrolyzed flour baked goods (S1BG) (2480 ppm residual gluten; n = 2), or fully hydrolyzed baked goods (S2BG) (8 ppm residual gluten; n = 5) for 60 days. Results: Two of the 6 patients who consumed NFBG discontinued the challenge because of symptoms; all had increased levels of anti-tissue transglutaminase (tTG) antibodies and small bowel deterioration. The 2 patients who ate the S1BG goods had no clinical complaints but developed subtotal atrophy. The 5 patients who ate the S2BG had no clinical complaints; their levels of anti-tTG antibodies did not increase, and their Marsh grades of small intestinal mucosa did not change. Conclusions: A 60-day diet of baked goods made from hydrolyzed wheat flour, manufactured with sourdough lactobacilli and fungal proteases, was not toxic to patients with CD. A combined analysis of serologic, morphometric, and immunohistochemical parameters is the most accurate method to assess new therapies for this disorder.

Details

Language :
English
Database :
OpenAIRE
Accession number :
edsair.doi.dedup.....1a9b2204da4832c4e3a5ec05fb7e2ba4